GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Oxford Immunotec Global PLC (NAS:OXFD) » Definitions » Quick Ratio

Oxford Immunotec Global (Oxford Immunotec Global) Quick Ratio : 14.85 (As of Sep. 2020)


View and export this data going back to 2013. Start your Free Trial

What is Oxford Immunotec Global Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Oxford Immunotec Global's quick ratio for the quarter that ended in Sep. 2020 was 14.85.

Oxford Immunotec Global has a quick ratio of 14.85. It generally indicates good short-term financial strength.

The historical rank and industry rank for Oxford Immunotec Global's Quick Ratio or its related term are showing as below:

OXFD' s Quick Ratio Range Over the Past 10 Years
Min: 1.3   Med: 6.28   Max: 16.1
Current: 14.85

During the past 9 years, Oxford Immunotec Global's highest Quick Ratio was 16.10. The lowest was 1.30. And the median was 6.28.

OXFD's Quick Ratio is not ranked
in the Medical Diagnostics & Research industry.
Industry Median: 1.91 vs OXFD: 14.85

Oxford Immunotec Global Quick Ratio Historical Data

The historical data trend for Oxford Immunotec Global's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford Immunotec Global Quick Ratio Chart

Oxford Immunotec Global Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Quick Ratio
Get a 7-Day Free Trial Premium Member Only 6.10 4.04 5.05 11.61 14.82

Oxford Immunotec Global Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.65 14.82 13.53 16.10 14.85

Competitive Comparison of Oxford Immunotec Global's Quick Ratio

For the Diagnostics & Research subindustry, Oxford Immunotec Global's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford Immunotec Global's Quick Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Oxford Immunotec Global's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Oxford Immunotec Global's Quick Ratio falls into.



Oxford Immunotec Global Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Oxford Immunotec Global's Quick Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Quick Ratio (A: Dec. 2019 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(215.881-11.096)/13.819
=14.82

Oxford Immunotec Global's Quick Ratio for the quarter that ended in Sep. 2020 is calculated as

Quick Ratio (Q: Sep. 2020 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(188.372-13.099)/11.801
=14.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxford Immunotec Global  (NAS:OXFD) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Oxford Immunotec Global Quick Ratio Related Terms

Thank you for viewing the detailed overview of Oxford Immunotec Global's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford Immunotec Global (Oxford Immunotec Global) Business Description

Traded in Other Exchanges
N/A
Address
143 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4SE
Oxford Immunotec Global PLC is a diagnostic company. It is focused on developing and commercializing proprietary tests for the management of underserved immune regulated conditions. Its products include T-spot TB, T-spot-CMV, T-spot PRT,T-cell extend etc. The company's research and development activities focus on Chronic infections, Transplantation, Autoimmune and Inflammatory disease, Immune oncology.
Executives
Andrew Scott Walton director 430 SOUTH SPRING STREET, BURLINGTON NC 27215
Mark R. Klausner director C/O OXFORD IMMUNOTEC GLOBAL 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Patricia Randall director C/O OXFORD IMMUNOTEC GLOBAL 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Richard A Sandberg director 330 NEVEDA STREET, NEWTON MA 02460-1458
Patrick J Balthrop director C/O MAXCYTE, INC., 9713 KEY WEST AVENUE, SUITE 400, ROCKVILLE MD 20850
Herm Rosenman director OXFORD IMMUNOTEC GLOBAL PLC, 94C INNOVATION DRIVE, HILTON PARK, SAN DIEGO X0 OX14 4RZ
James R Tobin director C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ronald Asbury Andrews director 5791 VAN ALLEN WAY, CARLSBAD CA 92008
Peter Wrighton-smith director, officer: Chief Executive Officer C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE ABINGDON X0 OX14 4RZ
Mclaughlin Matthew T E officer: Chief Financial Officer C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Stefan C Linn officer: Chief Operating Officer C/O OXFORD IMMUNOTEC GLOBAL 940 INNOVATION DRIVE MILTON PARK ABINGDON X0 OX14 4RZ
Janet Louise Kidd officer: General Counsel C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RZ
Elizabeth M Keiley officer: SVP & General Counsel C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Richard M. Altieri officer: Chief Financial Officer C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE ABINGDON X0 OX14 4RZ
Richard Wenstrup officer: Chief Medical Officer C/O OXFORD IMMUNOTEC GLOBAL, 94C INNOVATION DRIVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RZ

Oxford Immunotec Global (Oxford Immunotec Global) Headlines

From GuruFocus